Inflammatory Bowel Diseases Benefit from Enhanced Recovery After Surgery [ERAS] Protocol : A Systematic Review with Practical Implications
Vigorita, V. (Complexo Hospitalario Universitario de Vigo)
Cano-Valderrama, O. (Complexo Hospitalario Universitario de Vigo)
Celentano, Valerio (Imperial College London)
Vinci, Danilo (Policlinico Tor Vergata-University Tor Vergata)
Millan, Monica (Hospital Universitari i Politècnic La Fe (València))
Spinelli, Antonino (Humanitas Research Hospital (Itàlia))
Pellino, Gianluca (Hospital Universitari Vall d'Hebron)
Universitat Autònoma de Barcelona. Departament de Cirurgia

Data:	2022
Resum:	Background: Enhanced Recovery After Surgery [ERAS] is widely adopted in patients undergoing colorectal surgery, with demonstrated benefits. Few studies have assessed the feasibility, safety, and effectiveness of ERAS in patients with inflammatory bowel diseases [IBD]. The aim of this study was to investigate the current adoption and outcomes of ERAS in IBD. Methods: This PRISMA-compliant systematic review of the literature included all articles reporting on adult patients with IBD who underwent colorectal surgery within an ERAS pathway. PubMed/MEDLINE, Cochrane Library, and Web of Science were searched. Endpoints included ERAS adoption, perioperative outcomes, and ERAS items more consistently reported, with associated evidence levels [EL] [PROSPERO CRD42021238653]. Results: Out of 217 studies, 16 totalling 2347 patients were included. The median number of patients treated was 50. 5. Malnutrition and anaemia optimisation were only included as ERAS items in six and four articles, respectively. Most of the studies included the following items: drinking clear fluids until 2 h before the surgery, fluid restriction, nausea prophylaxis, early feeding, and early mobilisation. Only two studies included postoperative stoma-team and IBD-team evaluation before discharge. Highest EL were observed for ileocaecal Crohn's disease resection [EL2]. Median in-hospital stay was 5. 2 [2. 9-10. 7] days. Surgical site infections and anastomotic leaks ranged between 3. 1-23. 5% and 0-3. 4%, respectively. Complications occurred in 5. 7-48%, and mortality did not exceed 1%. Conclusions: Evidence on ERAS in IBD is lacking, but this group of patients might benefit from consistent adoption of the pathway. Future studies should define if IBD-specific ERAS pathways and selection criteria are needed.
Drets:	Aquest material està protegit per drets d'autor i/o drets afins. Podeu utilitzar aquest material en funció del que permet la legislació de drets d'autor i drets afins d'aplicació al vostre cas. Per a d'altres usos heu d'obtenir permís del(s) titular(s) de drets.
Llengua:	Anglès
Document:	Article de revisió ; recerca ; Versió acceptada per publicar
Matèria:	Inflammatory bowel disease ; Crohn's disease ; Crohn's disease Ulcerative colitis ; Colorectal surgery ; Enhanced recovery after surgery
Publicat a:	Journal of Crohn's and colitis, Vol. 16, Num. 5 (November 2022) , p. 845-851, ISSN 1876-4479

DOI: 10.1093/ecco-jcc/jjab209

Postprint 23 p, 645.0 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats